Want to see TGTX full AI Analyst Report?
TGTX Stock Chart & Stats
$35.33
$0.31(1.11%)
At close: 4:00 PM EST
$35.33
$0.31(1.11%)
Day’s Range― - ―
52-Week Range$25.28 - $59.30
Previous CloseN/A
Volume723.16K
Average Volume (3M)2.71M
Market Cap
$8.40B
Enterprise Value$5.56K
Total Cash (Recent Filing)$514.43M
Total Debt (Recent Filing)$753.56M
Price to Earnings (P/E)17.0
Beta0.63
Next Earnings
Aug 10, 2026EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.18
Shares Outstanding153,083,570
10 Day Avg. Volume2,064,287
30 Day Avg. Volume2,706,966
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)6.64
Price to Sales (P/S)6.98
P/FCF Ratio-172.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$55.86Price Target Upside58.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)1.33
Revenue Forecast (FY)$942.22M
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained high gross and net margins indicate durable pricing power and operating leverage from BRIUMVI sales. Such margin structure supports reinvestment, lifecycle programs and shareholder returns, provided commercial volume and payer dynamics remain stable over the medium term.
Stronger Balance SheetA materially cleaner balance sheet with minimal debt and expanded assets increases financial flexibility to fund subcutaneous scale-up, clinical programs, and opportunistic buybacks or M&A. Low leverage reduces refinancing risk and preserves optionality through 2–6 months and beyond.
Robust Commercial MomentumRapid patient adoption, consecutive quarterly growth and a guidance raise signal durable market penetration, physician acceptance, and expanding real-world use. This commercial traction underpins sustained revenue growth potential and supports funding of lifecycle investments.
Bears Say
Weak Cash GenerationPersistent negative operating and free cash flow despite reported profits highlights a quality-of-earnings gap driven by working capital or non‑cash items. Until cash generation turns sustainably positive, financial flexibility and ability to self-fund expansion remain constrained.
High Gross-to-Net PressureA ~65% gross‑to‑net implies large rebates/discounts that materially reduce realized revenues and margin conversion. This structural payer dynamic requires higher volumes to sustain net growth and makes long-term revenue visibility more sensitive to formulary and reimbursement shifts.
Governance HeadwindA failed say‑on‑pay vote signals investor dissatisfaction with compensation alignment and may spur board reforms or distractions. Governance tensions can create strategic uncertainty, heighten activism risk, and complicate retention/ incentive design for management over the medium term.
TG Therapeutics News
TGTX FAQ
What was TG Therapeutics’s price range in the past 12 months?
TG Therapeutics lowest stock price was $25.28 and its highest was $59.30 in the past 12 months.
What is TG Therapeutics’s market cap?
TG Therapeutics’s market cap is $8.40B.
When is TG Therapeutics’s upcoming earnings report date?
TG Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 19 days.
How were TG Therapeutics’s earnings last quarter?
TG Therapeutics released its earnings results on May 06, 2026. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.275 by -$0.155.
Is TG Therapeutics overvalued?
According to Wall Street analysts TG Therapeutics’s price is currently Undervalued.
Does TG Therapeutics pay dividends?
TG Therapeutics does not currently pay dividends.
What is TG Therapeutics’s EPS estimate?
TG Therapeutics’s EPS estimate is 0.32.
How many shares outstanding does TG Therapeutics have?
TG Therapeutics has 153,083,570 shares outstanding.
What happened to TG Therapeutics’s price movement after its last earnings report?
TG Therapeutics reported an EPS of $0.12 in its last earnings report, missing expectations of $0.275. Following the earnings report the stock price went up 16.26%.
Which hedge fund is a major shareholder of TG Therapeutics?
Currently, no hedge funds are holding shares in TGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TG Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$55.86 (58.10% Upside)
$55.86 (58.10% Upside)
Blogger Sentiment
Bullish
TGTX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 536.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
132.81%
Trailing 12-Months
Company Description
TG Therapeutics
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
TGTX Stock 12 Month Forecast
Average Price Target
$55.86
▲(58.10% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Nuvalent
―
Ownership Overview
7.54% Insiders
18.43% Mutual Funds
1.88% Other Institutional Investors
47.53% Public Companies and
Individual Investors